Article

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

2023-01-02

Abstract excerpt

BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead as single agents to long-lasting complete remission is rather limited especially in the lymphoma setting. This indicates that tumor cells often develop resistance to the drugs. Here, we show that the overexpression of ERBB4 and its ligands represents a modality for B ce...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef68cc69-5042-58ce-afb1-de27d7d8161e
DOI: 10.1101/2023.01.01.522017

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsDOI 10.1101/2023.01.01.522017Read

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Semantic proximity Read

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read

Overcoming Acquired Epigenetic Resistance to BTK InhibitorsSemantic proximity Read

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Semantic proximity Read

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.Semantic proximity Read

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone LymphomaSemantic proximity Read

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma CellsSemantic proximity Read

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasSemantic proximity Read